Introduction
============

Most patients with squamous cell carcinoma of the head and neck (HNSCC) present with locally advanced disease (stage III--IV), and 5-year overall survival (OS) rates with multimodality treatment are 40--60% [@b1]. Induction chemotherapy (IC) may be employed as a treatment strategy for locally advanced HNSCC, as it has the advantages of potential organ preservation, early identification of patients likely to benefit from chemoradiotherapy (CRT), and decreased incidence of distant metastases. The most widely used IC regimen is docetaxel, cisplatin, and fluorouracil (TPF), based on two randomized trials that showed a survival benefit with docetaxel added to cisplatin and fluorouracil (PF) [@b2],[@b3].

*Nab*-paclitaxel is a microtubule inhibitor formulated as a colloidal suspension of paclitaxel and human serum albumin. Preclinical studies suggest that albumin binding to cell surface receptors can facilitate transport of *nab*-paclitaxel into tumor cells [@b4]. We recently published results of a prospective phase 2 trial investigating a novel induction regimen of *nab*-paclitaxel, cisplatin, and fluorouracil with cetuximab (APF-C), followed by CRT [@b5]. Survival outcomes in patients treated with APF-C followed by CRT were very favorable, with a relapse rate of only 13%.

We hypothesized that a *nab*-paclitaxel-based compared to a docetaxel-based IC regimen would be better in terms of survival endpoints. We compared survival outcomes of patients treated with APF-C to institutional historical controls who received TPF plus cetuximab (TPF-C). Both groups were subsequently scheduled to receive CRT with cisplatin.

Materials and Methods
=====================

Patient population
------------------

All patient data were collected through an institutional review board (IRB)-approved retrospective analysis. Patients treated with APF-C (*n *=* *30) were enrolled onto an IRB-approved prospective phase 2 trial at our institution between 2009 and 2010 (clinicaltrials.gov NCT00736944). The results of this trial were published, but were updated for this analysis [@b5]. The historical comparison group consisted of patients who received IC with TPF-C (*n *=* *38) and were enrolled onto an IRB-approved head and neck registry between 2006 and 2010. Eligibility criteria for both IC groups included untreated Stage III and IVa/b HNSCC, Eastern Cooperative Oncology Group (ECOG) performance status of 0--1, T2--4 classification, and plan to receive three cycles of IC followed by cisplatin concurrent with definitive RT.

Treatment regimens
------------------

### Induction chemotherapy

The APF-C group was treated with every 3-week cycles of IV *nab*-paclitaxel 100 mg/m^2^ on days 1, 8, and 15, cisplatin 75 mg/m^2^ on day 1, 5-FU 750 mg/m^2^ continuous IV infusion (CIVI) daily on days 1--3, and cetuximab 400 mg/m^2^ day 1 and 250 mg/m^2^ weekly subsequently [@b5]. The TPF-C group was treated with every 3-week cycles of docetaxel 75 mg/m^2^ and cisplatin 75 mg/m^2^ on day 1, 5-FU 750 mg/m^2^ CIVI daily on days 1--3, and cetuximab 400 mg/m^2^ day 1 and 250 mg/m^2^ weekly subsequently. Three cycles of IC were planned for both groups.

### Definition of primary tumor site response criteria

Response at the primary tumor site was determined by visual analysis by the otolaryngologist after 2 cycles of IC. Response was categorized as complete response (CR: complete resolution of the primary tumor), partial response (PR: greater than 50% decrease but less than CR), stable disease (SD: 0--49% decrease) or progressive disease (PD: any increase), as previously described [@b5]. Patients with favorable response (CR/PR) at the primary site proceeded to CRT after cycle 3 of IC. Surgical intervention was considered in patients with an unfavorable (SD/PD) tumor response at the primary site.

### Chemoradiotherapy

CRT was started after the final cycle of IC. Intensity-modulated radiation therapy (IMRT) was administered once daily, 5 days weekly, as previously described [@b5]. The APF-C and TPF-C groups received cisplatin 100 mg/m^2^ on day 1, 22, and 43 if creatinine \<2.0 (if not, cetuximab was administered, as previously described) [@b5].

Standard assessments
--------------------

Baseline assessments included history and physical examination, laryngoscopy, computed tomography (CT) of the neck, and F-18 fluorodeoxyglucose positron emission tomography/CT (FDG-PET/CT). Assessments of adverse events (AEs) were performed using National Cancer Institute--Common Toxicity Criteria (NCI-CTC) version 3.0. After two cycles of IC, patients underwent assessment of tumor response by clinical examination and CT neck [@b5]. Subsequent follow-up was performed as previously reported [@b5]. Comorbidities were quantified using the Adult Comorbidity Evaluation (ACE)-27 index [@b6].

### p16

Immunohistochemistry for p16, a surrogate for human papillomavirus (HPV), was performed on oropharyngeal (OP) tumors, as previously described [@b7] and was scored by the pathologist (JSL) as positive when ≥50% of tumor cells showed nuclear and cytoplasmic staining.

Statistical methods
-------------------

Demographic and disease characteristics of the patients were summarized using descriptive statistics. Treatment differences regarding response rates at the primary tumor site were examined using Cochran--Mantel--Haenszel, and Fisher\'s exact test for unordered or fewer than 3 categories and Jonckheere tests for ordinal trend for 3 or more categories. Disease-specific survival (DSS) was estimated by the cumulative incidence method to account for competing risks of death due to treatment-related or other causes. Cox proportional hazards models were used to estimate cause-specific hazards.

OS was defined as time from diagnosis to death or to last follow-up alive. Progression-free survival (PFS) was defined as time from diagnosis to death due to disease progression, to disease progression, or to last follow-up alive. DSS was defined as time from diagnosis to death from disease or to last follow-up alive.

Results
=======

Patient and tumor characteristics
---------------------------------

A number 68 patients were included in this analysis: 30 in the APF-C group and 38 in the TPF-C group. Baseline characteristics including T&N classification, smoking history, and primary tumor site were similar between the two groups (Table[1](#tbl1){ref-type="table"}). A larger proportion of patients in the APF-C group (57%) had p16-positive OPSCC in comparison to the TPF-C group (34.1%) (*P *=* *0.068). Therefore, survival outcome analyses were stratified for this important prognostic variable. Importantly, in either the p16-positive or p16-negative subsets, there were no significant differences in the proportions of patients who smoked, who had T2, T3, or T4 classification, or who had N0/1, N2 or N3 classification in the APF-C compared to the TPF-C groups (data not shown).

###### 

Patient and tumor characteristics

                                                APF-C (*n *=* *30)   TPF-C (*n *=* *38)   *P* value                                   
  --------------------------------------------- -------------------- -------------------- -------------------------------------- ---- ---------------------------------------
  Characteristic                                                                                                                      
   Age (years)                                                                                                                        
   Median                                       57                   55                   0.95[2](#tf1-2){ref-type="table-fn"}        
   Range                                        38--71               38--72                                                           
   Sex                                                                                                                                
   Male                                         28                   93                   34                                     90   0.69[3](#tf1-3){ref-type="table-fn"}
   Female                                       2                    7                    4                                      10   
   Smoking history                                                                                                                    
   Yes                                          27                   90                   35                                     92   0.99[3](#tf1-3){ref-type="table-fn"}
   No                                           3                    10                   3                                      8    
   ACE comorbidity index                                                                                                              
   0 (none)                                     9                    30                   9                                      24   0.12[4](#tf1-4){ref-type="table-fn"}
   1 (mild)                                     2                    7                    17                                     45   
   2 (moderate)                                 13                   43                   9                                      24   
   3 (severe)                                   6                    20                   3                                      8    
   Primary site                                                                                                                       
   Oropharynx                                   22                   73                   25                                     66   0.57[3](#tf1-3){ref-type="table-fn"}
   Larynx                                       7                    23                   12                                     32   
   Hypopharynx                                  0                    0                    1                                      3    
   Oral cavity                                  1                    3                    0                                      0    
   T classification                                                                                                                   
   T2                                           8                    27                   5                                      13   0.27[4](#tf1-4){ref-type="table-fn"}
   T3                                           11                   37                   16                                     42   
   T4                                           11                   37                   17                                     45   
   N classification                                                                                                                   
   N0 and N1                                    6                    20                   10                                     26   0.83[4](#tf1-4){ref-type="table-fn"}
   N2a/b                                        6                    20                   9                                      24   
   N2c                                          14                   47                   10                                     26   
   N3                                           4                    13                   9                                      24   
   p16 positive                                                                                                                       
   Oropharynx[1](#tf1-1){ref-type="table-fn"}   17                   57                   13                                     34   0.068[3](#tf1-3){ref-type="table-fn"}

Two patients with oropharynx HNSCC did not have p16 staining performed and are not included in these data. Overall, there were 47 patients with oropharynx tumors, 30 of whom were p16 positive and were included here.

*P*-value from a *t*-test.

Fisher\'s exact test.

Jonckheere--Terpstra test (for trend over an ordinal variable).

Treatment delivery
------------------

Treatment delivery details are described in Table[2](#tbl2){ref-type="table"}. Here 100% of the APF-C and the TPF-C groups completed 2 or more IC cycles, 97% of APF-C, and 84% of TPF-C patients received 3 IC cycles.

###### 

Treatment delivery

  Treatment                      APF-C (*n *=* *30)   TPF-C (*n *=* *38)                                 
  ------------------------------ -------------------- ---------------------------------- --------------- ----------------------------------
  Induction chemotherapy                                                                                 
   *nab*-Paclitaxel              100 (67--100)        14 (47)                            --              --
   Docetaxel                     --                   --                                 100 (67--100)   11 (29)
   Cetuximab                     100 (27--100)        14 (47)                            89 (0--100)     21 (57)
   Cisplatin                     100 (67--100)        2 (7)                              100 (67--100)   8 (21)
   Fluorouracil                  100 (80--100)        2 (7)                              100 (58--100)   14 (37)
  Chemoradiotherapy                                   [1](#tf2-1){ref-type="table-fn"}                   [2](#tf2-2){ref-type="table-fn"}
   Radiation therapy             *n *=* *29                                              *n *=* *34      
   Median dose Gy (range)        70 (14--72)          3 (10)                             70 (70----72)   4 (11)
   Median elapsed days (range)   50 (8--69)                                              50 (37--64)     
   Concurrent chemotherapy       *n *=* *28                                              *n *=* *34      
   Cisplatin (% patients)        27 (93)                                                 29 (85)         
   % Total dose (range)          76 (33--100)         17 (57)                            71 (33--100)    27 (71)
   Cetuximab (% patients)        1 (4)                                                   5 (15)          

Denominator is 30 patients.

Denominator is 38 patients.

Twenty-nine of 30 (96.7%) patients given APF-C and 34 of 38 (89.5%) patients given TPF-C received IMRT. Reasons that patients did not receive IMRT included treatment-related mortality (TRM) during IC (*n *=* *2), metastatic disease progression occurring during comorbidity-related treatment delay (*n *=* *1), surgery following IC with no adjuvant therapy (*n *=* *1), and lost to follow-up (*n *=* *1). The IMRT delivery was similar across the two IC groups. The majority of patients in the APF-C (93%) and TPF-C (85%) groups received cisplatin concurrent with IMRT. Others received cetuximab concurrent with IMRT.

Primary tumor site response after 2 cycles of IC
------------------------------------------------

The overall response rate at the primary site after 2 cycles of IC was 100% for APF-C and 84% for TPF-C (*P *=* *0.031). Progressive or stable disease after 2 cycles of TPF-C was seen in 13% (*n *=* *5) and 3% (*n *=* *1) of patients, respectively. Patients treated with APF-C had a greater risk of overall response at the primary tumor site than those treated with TPF-C after adjusting for p16 status (relative risk = 1.17; 95% confidence interval \[CI\]: 1.02--1.34).

Overall, the CR rate at the primary site was 53.3% for APF-C compared to 34.2% for TPF-C (*P *=* *0.14). In p16-positive OPSCC, the CR rate at the primary tumor site was 64.7% for APF-C and 38.5% for TPF-C (*P *=* *0.27). In p16 negative HNSCC, the CR rate was 33.3% for APF-C and 33.3% for TPF-C (*P *=* *0.99).

Neck nodal and overall tumor site response after 2 cycles of IC
---------------------------------------------------------------

The tumor response rates at neck nodal sites after 2 cycles of APF-C and TPF-C respectively, based on clinical examinations were 61% CR (11 patients) compared to 45% CR (13 patients) and 39% PR (7 patients) compared to 48% PR (14 patients). In the APF-C group, the neck nodes of all patients who were evaluated responded, but in the TPF-C group stable or progressive nodal disease was seen in 7% (2 patients). Twelve patients in the APF-C group and 9 patients in the TPF-C group were not evaluable for this endpoint because of initial absence of nodal disease on clinical examination.

The overall tumor response rates for APF-C were 43% CR, 57% PR, and 0% SD/PD, whereas the overall tumor response rates for TPF-C were 26% CR, 58% PR, and 16% SD/PD.

Disease-specific survival
-------------------------

The median duration of follow-up for living patients in the APF-C group was 43.5 (range: 30--58) months versus 52 (range: 13--84) months for TPF-C. All but 4 of the living patients had a minimum of 2 years of follow-up.

Two-year DSS was 96.7% (CI: 85.2%, 99.8%) for patients given APF-C compared to 77.6% (CI: 62.6%, 89.7%) for patients given TPF-C (*P *=* *0.0004) (Fig.[1](#fig01){ref-type="fig"}A). Table[3](#tbl3){ref-type="table"} displays the univariate analysis of proportions of treatment failures due to disease for patient, tumor, and treatment characteristics. Given the prognostic significance of HPV in HNSCC [@b8], we stratified DSS for p16 status and treatment group. The 2-year DSS of patients with p16-positive OPSCC was 100% for APF-C (*n *=* *17) and 74.6% (CI: 47.4%, 94.6%) for TPF-C (*n *=* *13) (*P *=* *0.0019) (Fig.[1](#fig01){ref-type="fig"}B). Two-year DSS of patients with p16 negative HNSCC was 91.7% (CI: 67.6%, 99.6%) for APF-C (*n *=* *12) versus 82.6% (CI: 64.4%, 94.8%) for TPF-C (*n *=* *24) (*P *=* *0.092).

###### 

Univariate analysis for DSS.

  -------------------------------------------------------------------------------------
  Variable                           Failed/total no. patients   Log-rank *P* value
  ---------------------------------- --------------------------- ----------------------
  Patient characteristics                                        

   Gender                                                        

    Male                             16/62                       0.99

    Female                           0/6                         

   Smoking                                                       

    Yes                              15/62                       0.59

    No                               1/6                         

   ACE comorbidity score                                         

    None/mild                        11/37                       0.18

    Moderate/severe                  5/31                        

  Tumor characteristics                                          

   Primary tumor site                                            

    Oropharynx                       11/47                       0.93

    Larynx/hypopharynx/oral cavity   5/21                        

   T classification                                              

    T4                               10/28                       0.46 (T3 vs. T2)\
                                                                 0.095 (T4 vs. T2)

    T3                               5/27                        

    T2                               1/13                        

   N classification                                              

    N3                               7/13                        0.46 (N2 vs. N0/N1)\
                                                                 0.022 (N3 vs. N0/N1)

    N2                               7/39                        

    N0/1                             2/16                        

   p16                                                           

    Negative                         9/36                        0.47

    Positive                         6/30                        

  Treatment characteristics                                      

   CR at primary site                                            

    No                               12/39                       0.24

    Yes                              4/29                        

   Treatment group                                               

    TPF-C                            15/38                       0.0064

    APF-C                            1/30                        
  -------------------------------------------------------------------------------------

![Survival outcomes in the APF-C and TPF-C groups. (A) DSS, (B) DSS by p16 status and treatment group, (C) PFS, (D) OS.](cam40004-0481-f1){#fig01}

Progression-free and overall survival
-------------------------------------

Overall, 2-year PFS was 89.3% for APF-C and 55.7% for TPF-C (*P *=* *0.0019) (Fig.[1](#fig01){ref-type="fig"}C). Two-year PFS for patients with p16-positive OPSCC was 93.8% for APF-C and 68.4% for TPF-C (*P *=* *0.034). The 2-year PFS for patients with p16 negative HNSCC was 81.8% for APF-C, and 51.2% with TPF-C (*P *=* *0.091).

Overall, 2-year OS was 90.0% for APF-C and 66.6% for TPF-C (*P *=* *0.0008) (Fig.[1](#fig01){ref-type="fig"}D). The 2-year OS for patients with p16-positive OPSCC was 94.1% for APF-C and 74.6% for TPF-C (*P *=* *0.013). The 2-year OS for patients with p16 negative HNSCC was 83.3% for APF-C and 65.4% for TPF-C (*P *=* *0.088).

Causes of death
---------------

Causes of death are shown in Table[4](#tbl4){ref-type="table"}. Disease progression resulting in death was more common in the TPF-C group (39%) compared to the APF-C group (3%). A competing risks model (Gray\'s test) [@b9] was used to differentiate deaths due to disease progression from other causes of death without censoring deaths of other causes. This model showed that the incidence of death due to disease progression was greater in the TPF-C group compared to the APF-C group (*P *=* *0.0004). The hazard of death due to disease progression is 94% lower in the APF-C group than in the TPF-C group (HR = 0.060 \[CI: 0.008, 0.45\]). There was no difference in the hazard ratios of TRM or death of other causes (second malignancy and noncancer death) in the two treatment groups (TRM:HR = 0.632 \[CI: 0.057, 6.97\]); death of other causes \[HR = 0.701 (CI: 0.116, 4.24)\] (Fig.[2](#fig02){ref-type="fig"}).

###### 

Cause of death and selected adverse events occurring with IC and CRT

                                               APF-C and CRT (*n *=* *30)   TPF-C and CRT (*n *=* *38)   *P* value[2](#tf4-2){ref-type="table-fn"}
  -------------------------------------------- ---------------------------- ---------------------------- -------------------------------------------
  Cause of death                                                                                         
   Disease progression                         1 (3)                        15 (39)                      --
   Second malignancy                           0 (0)                        1 (3)                        --
   Treatment-related                           1 (3)                        2 (5)                        --
   Noncancer[1](#tf4-1){ref-type="table-fn"}   2 (6)                        2 (5)                        --
   Total                                       4 (13)                       20 (53)                      --

  Adverse event          Grade 3 or 4   All grades   Grade 3 or 4   All grades   
  ---------------------- -------------- ------------ -------------- ------------ ---------
  Neuropathy             1 (3)          17 (57)      1 (3)          4 (11)       0.00014
  Hypersensitivity       1 (3)          4 (13)       2 (5)          11 (29)      0.15
  Rash                   6 (20)         28 (93)      5 (13)         29 (76)      0.096
  Mucositis              9 (30)         25 (83)      13 (34)        26 (68)      0.26
  Creatinine elevation   2 (7)          18 (60)      1 (3)          7 (18)       0.00085

Includes bowel obstruction (*n* = 1) and unknown (*n* = 2).

*P* value is for comparison of all grades of toxicities, *P*-values from Fisher\'s Exact test.

![Cumulative incidence of death due to disease in the APF-C and TPF-C groups.](cam40004-0481-f2){#fig02}

Site of relapse and salvage surgery
-----------------------------------

Four patients (13%) in the APF-C group developed relapse (3 local/regional, 1 distant). In the TPF-C group, 17 patients (45%) developed relapse (8 local/regional, 5 distant, 4 both).

An unfavorable response to IC occurred in 6 patients (5 PD;1 SD); one of these patients underwent salvage surgery and 5 proceeded to CRT (patient/physician preference or not surgical candidate). Following CRT, 1 patient in the APF-C group underwent a neck dissection for a residual neck mass and the pathology was negative for malignancy. In the TPF-C group, 1 patient underwent post-treatment resection of residual malignancy.

Adverse events
--------------

Table[4](#tbl4){ref-type="table"} summarizes the AEs related to treatment during IC and CRT. Neuropathy and creatinine elevation were more frequent with APF-C, although most were grade 1--2.

Discussion
==========

This study is a historical comparison of survival outcomes of different taxane-based IC regimens in HNSCC. Patients treated with the *nab*-paclitaxel-based IC regimen (APF-C) followed by CRT had better 2-year DSS and OS and a lower hazard of death due to disease progression compared to the docetaxel-based regimen (TPF-C) followed by CRT. T and N classifications and smoking history were balanced between the two treatment groups and within p16-positive and p16-negative subsets. Differences in the proportion of patients with p16-positive tumors existed, favoring better outcomes in the APF-C group. However, it was within the p16-positive OPSCC subset that we observed significantly better 2-year DSS and OS with APF-C compared to TPF-C (DSS: 100% vs. 74.6%, *P *=* *0.0019 and OS: 94.1% vs. 74.6%, *P *=* *0.013, respectively).

Relapse of disease was more frequent in the TPF-C group compared to the APF-C group (Kaplan--Meier estimate 51.8% vs. 16%, respectively at 41 months). Given the mix of p16 negative HNSCC and p16-positive OPSCC patients, both of which were enriched for smoking history and bulky disease, the risk of relapse of disease was very low with APF-C. In the TAX 324 and Paradigm trials, relapse of disease occurred in 56% and 24% of patients given TPF followed by CRT, respectively [@b3],[@b10],[@b11]. The higher risk of relapse of disease observed with TPF-C in comparison to TPF in the Paradigm trial may reflect the greater proportion of patients with T3/4 and N2c/3 classification in our study.

The 2-year PFS and OS were 89.3%, and 90%, respectively, for all patients treated with APF-C. Recognizing the potential pitfalls of cross-study comparisons, these findings compare very favorably to contemporary studies of TPF followed by CRT, with 2 or 3-year PFS rates of 54-67% and 2 or 3-year OS rates of 67--73% [@b10],[@b11]. Absolute PFS and OS with APF-C were better than with TPF in the TAX 324 trial in p16 negative HNSCC (2-year PFS 75% and 35%, respectively; 2-year OS 83.3% and 48%, respectively) and p16-positive OPSCC (2-year PFS 88.2% and 83%, respectively; 2-year OS 94% and 89%, respectively) [@b11]. Cetuximab has been incorporated into docetaxel-containing IC, with 3-year PFS and OS of 70% and 74%, respectively [@b12].

Two questions arise about the relative contributions of components of APF-C. Is *nab*-paclitaxel better than cremophor-based paclitaxel in HNSCC and is there a role for cetuximab in IC? A comparison of cremophor-based paclitaxel and PF to PF showed no significant difference in 2-year OS (66.5% vs. 53.6%, respectively) [@b13]. Although cross-study comparisons have limitations, the 2-year OS (90%) results with APF-C compare more favorably than these data. SPARC (secreted protein acidic and rich in cysteine) plays a role in albumin receptor-mediated endothelial transport [@b14]. SPARC expression is common in tumor and stromal cells of HNSCC but not in adjacent normal oral mucosa [@b15], and correlated with tumor response to nab-paclitaxel in HNSCC in one study [@b4]. Macropinocytosis, the process by which macromolecules like albumin are taken up into cells, is upregulated in the setting of activated RAS or PI3K pathways [@b16]. RAS and/or components of the PI3K pathways are frequently activated in HNSCC [@b17]--[@b22], in particular p16-positive OPSCC, and could explain the high anti-tumor effect of *nab*-paclitaxel in HNSCC. Collectively, these data suggest but do not prove that *nab*-paclitaxel may be better than cremophor-based paclitaxel in HNSCC.

With respect to the second question, the EXTREME trial showed that the addition of cetuximab to chemotherapy improved tumor response rates and OS in patients with incurable HNSCC [@b23]. Therefore, we anticipated an improvement in tumor response rates at the primary tumor site and 2-year survival outcomes with the addition of cetuximab to TPF and to APF. However, our trial was not designed to assess this hypothesis. We are prospectively evaluating nab-paclitaxel, cisplatin, and 5-fluorouracil (APF) without cetuximab as IC before CRT for HNSCC (NCT01566435) and plan to compare outcomes with the APF-C regimen.

IC is a controversial therapeutic strategy in HNSCC. While a few trials had shown an OS benefit with this approach [@b24],[@b25], other trials have not confirmed this. The two largest trials evaluating the role of IC with CRT were the PARADIGM and DeCIDE trials [@b10],[@b26]. Both studies randomized patients to CRT alone or TPF followed by CRT. Neither trial reached its target accrual or showed an OS benefit with TPF. Both trials were limited by the fact that the preplanned 3-year OS was 50--55%; however, the actual OS was higher (73% and 75%), lowering the statistical power. The DeCIDE trial did show improvements in recurrence-free survival and distant failure rates with TPF.

Given these results, is there a justification for further investigation of IC in HNSCC? A rational reason to administer IC is to use the tumor response to IC as a method to stratify patients into higher and lower risk groups. CR at the primary tumor site to IC is an important predictor of long-term DFS [@b27]. Those patients with a favorable response at the primary tumor site to IC could be candidates for deintensification of definitive therapy, and those with unfavorable response to IC may benefit from standard intensive therapy. This approach could substantially decrease the toxicity for lower risk patients. ECOG 1308 is a phase 2 trial investigating this novel reason to administer IC [@b28]. In our study, the CR rate at the primary tumor site in p16-positive OPSCC was 64.7% with APF-C compared to 38.5% with TPF-C. Therefore, APF-C may be an excellent IC regimen to employ for risk stratification in p16-positive OPSCC.

Rates of AEs in our series were similar to that published for TPF, as well as IC regimens that incorporated cetuximab. In a large trial of TPF, the incidence of grade 3-4 events was 65% [@b2]. IC regimens with cetuximab showed rates of mucositis (77%) and rash (45%) similar to APF-C [@b29]. One TRM (3%) occurred in the APF-C group and 2 TRM (5%) in the TPF-C group. Peripheral neuropathy and creatinine elevation were more frequent in the APF-C group compared to the TPF-C group, although the majority of these AEs were grades 1--2.

Our study has limitations. This study was a retrospective analysis comparing outcomes in a prospective study with those of historical controls. The small sample size in each group limits the power of the statistical comparisons and the ability to control for heterogeneity in patient and tumor characteristics. We did not assess patient-reported quality of life in either treatment group. Also, cetuximab was included in both induction regimens; however, the role of cetuximab in this setting is unclear. This is a single institution experience that will require validation across institutions.

In conclusion, 2-year DSS and OS were significantly better with a *nab*-paclitaxel-based IC regimen (APF-C) compared to a docetaxel-based IC regimen (TPF-C) in p16-positive OPSCC. The outcomes support further research of *nab*-paclitaxel-based IC regimens in HNSCC.
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